» Articles » PMID: 29991529

Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells Through an AhR/GR/HIF-driven Signaling Axis

Abstract

The metastatic cascade is a complex process that requires cancer cells to survive despite conditions of high physiologic stress. Previously, cooperation between the glucocorticoid receptor (GR) and hypoxia-inducible factors (HIF) was reported as a point of convergence for host and cellular stress signaling. These studies indicated p38 MAPK-dependent phosphorylation of GR on Ser134 and subsequent p-GR/HIF-dependent induction of breast tumor kinase (PTK6/Brk), as a mediator of aggressive cancer phenotypes. Herein, p-Ser134 GR was quantified in human primary breast tumors ( = 281) and the levels of p-GR were increased in triple-negative breast cancer (TNBC) relative to luminal breast cancer. Brk was robustly induced following exposure of TNBC model systems to chemotherapeutic agents (Taxol or 5-fluorouracil) and growth in suspension [ultra-low attachment (ULA)]. Notably, both Taxol and ULA resulted in upregulation of the Aryl hydrocarbon receptor (AhR), a known mediator of cancer prosurvival phenotypes. Mechanistically, AhR and GR copurified and following chemotherapy and ULA, these factors assembled at the Brk promoter and induced Brk expression in an HIF-dependent manner. Furthermore, Brk expression was upregulated in Taxol-resistant breast cancer (MCF-7) models. Ultimately, Brk was critical for TNBC cell proliferation and survival during Taxol treatment and in the context of ULA as well as for basal cancer cell migration, acquired biological phenotypes that enable cancer cells to successfully complete the metastatic cascade. These studies nominate AhR as a p-GR binding partner and reveal ways to target epigenetic events such as adaptive and stress-induced acquisition of cancer skill sets required for metastatic cancer spread. Breast cancer cells enlist intracellular stress response pathways that evade chemotherapy by increasing cancer cell survival and promoting migratory phenotypes. .

Citing Articles

Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer.

Posani S, Gillis N, Lange C J Steroid Biochem Mol Biol. 2024; 243:106575.

PMID: 38950871 PMC: 11344665. DOI: 10.1016/j.jsbmb.2024.106575.


Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.

Robert S, Roman Ortiz N, LaRocca C, Ostrander J, Davydova J Viruses. 2024; 16(4).

PMID: 38675909 PMC: 11054319. DOI: 10.3390/v16040567.


Aryl hydrocarbon receptor: An emerging player in breast cancer pathogenesis and its potential as a drug target (Review).

Chen C, Wang Z, Liao Z, Zhang Y, Lei W, Shui X Mol Med Rep. 2023; 29(1).

PMID: 37997818 PMC: 10704547. DOI: 10.3892/mmr.2023.13134.


Prognostic impact of PTK6 expression in triple negative breast cancer.

Chen Y, Qu W, Tu J, Yang L, Gui X BMC Womens Health. 2023; 23(1):575.

PMID: 37932734 PMC: 10629122. DOI: 10.1186/s12905-023-02736-y.


Crosstalk between p38 MAPK and GR Signaling.

Zeyen L, Seternes O, Mikkola I Int J Mol Sci. 2022; 23(6).

PMID: 35328742 PMC: 8953609. DOI: 10.3390/ijms23063322.


References
1.
Peng M, Emmadi R, Wang Z, Wiley E, Gann P, Khan S . PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget. 2014; 5(15):6038-48. PMC: 4171611. DOI: 10.18632/oncotarget.2153. View

2.
Lew B, Collins L, OReilly M, Lawrence B . Activation of the aryl hydrocarbon receptor during different critical windows in pregnancy alters mammary epithelial cell proliferation and differentiation. Toxicol Sci. 2009; 111(1):151-62. PMC: 2726296. DOI: 10.1093/toxsci/kfp125. View

3.
Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

4.
Gatza M, Silva G, Parker J, Fan C, Perou C . An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet. 2014; 46(10):1051-9. PMC: 4300117. DOI: 10.1038/ng.3073. View

5.
Ostrander J, Daniel A, Lange C . Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol. 2010; 10(6):662-9. PMC: 2981671. DOI: 10.1016/j.coph.2010.08.007. View